Opna Bio is a clinical stage biopharmaceutical company focused on the discovery and development of novel oncology therapeutics. The company was founded to develop drugs aimed at disrupting the actions of an unprecedented new cancer target – fragile-X mental retardation protein (FMRP).

The role of FMRP in cancer was elucidated in the laboratory of Dr. Douglas Hanahan, co-founder of Opna Bio, and co-author of the seminal “Hallmarks of Cancer” series, which proposed a set of traits commonly acquired by human cancer cells and crucial for the formation of malignant tumors.

Core Programs

Opna Bio is focused on two core programs which address different hallmarks of cancer. In addition to its discovery-stage FMRP program, Opna Bio is developing OPN-6602, a best-in-class EP300/CBP inhibitor, for the treatment of multiple myeloma. The program is expected to enter the clinic in 2024.

View Pipeline

Opna Bio’s corporate headquarters are located in Lausanne, Switzerland with an additional site based in South San Francisco, CA.

Our team in Lausanne, see more

Our team IN SSF, see more

Experienced Series A investors

  • Longtitude Capital
  • Northpond Ventures
  • Menlo Ventures